Officials offer cash prizes to residents to fight back against slug invasion: 'Last summer, the situation got out of hand'
The so-called Spanish slug is an aggressive and invasive gastropod that does immense damage to crops throughout Europe. Despite its name, it's not clear where the species actually originated; as the Senckenberg Research Institute and Natural History Museum reported, German researchers could not find any of them in Spain.
Regardless of their native habitat, they have been a pain for dozens of European nations for decades. They are particularly abundant in southern Finland, which is why officials are offering a financial incentive to residents to help eradicate them.
"Last summer, the situation got out of hand," Maisa Hautala, city gardener in Lappeenranta, told the Helsinki Times. "We received an overwhelming number of reports about Spanish slugs."
To combat this scourge, residents are being offered the modest sum of €6 ($7.03) for every liter of slugs they dispatch. The payout is tied to an app; users upload footage of slugs being sealed in containers and dropped in designated waste bins.
Invasive species pose significant threats to biodiversity, as they outcompete indigenous plants and wildlife for resources. In this case, the hungry gastropods feast on their smaller native brethren and damage crops. Because some carry Escherichia coli, their mucus trails can contaminate the produce they contact. As Novia University of Applied Science notes, the slugs can self-fertilize and lay 2-400 eggs at a time, so even a single slug can quickly cause an infestation.
Cash incentives have been used to combat invasive species in other areas, while some communities take collective local action. There are different strategies, but the most effective remedy is prevention and strengthening an area's biodiversity with native flora. Such efforts begin at home. Rewilding a yard isn't just good for the ecosystem; it's much easier and cheaper to maintain.
What is stopping you from upgrading to a heat pump system?
The cost of installation
I live in a cold area
I don't know enough about it
I already have one
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&A session. The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at . To receive telephone dial-in information and a unique personal access PIN, please register at Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma's website at About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma's business and activities, please visit ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@ Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@ Anna Krassowska, PhD (Investor and Media)Vice President, Investor Relations & Corporate Communicationsakrassowska@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Avidity (RNA) Gets 26% Jump on Potential Takeover
We recently published . Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at $48.26 as investors gobbled up shares following reports that it received an acquisition bid from Swiss drugmaker Novartis AG (NYSE:NVS). A report by the Financial Times, citing people privy to the matter, said that Novartis AG (NYSE:NVS) offered Avidity Biosciences, Inc. (NASDAQ:RNA) to acquire the company, in line with the former's plans to boost its pipeline of medicines targeting rare genetic disorders. Meanwhile, the report said that Avidity Biosciences, Inc. (NASDAQ:RNA) was mulling over the offer, although the talks could still collapse as other companies have emerged with separate takeover offers. Late last month, Avidity Biosciences, Inc. (NASDAQ:RNA) secured a Breakthrough Therapy designation from the Food and Drug Administration for its del-zota treatment for Duchenne muscular dystrophy (DMD) in patients with DMD44. DMD is a rare genetic condition characterized by progressive muscle damage and weakness due to the loss of dystrophin protein that typically starts at a young age. Del-zota, on the other hand, was designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. While we acknowledge the potential of RNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .


Fox News
2 hours ago
- Fox News
Coffee vs. matcha: Is your morning brew helping or hurting your health?
Tim Spector, a King's College London professor of epidemiology and a leading microbiome researcher, dives into the science, benefits and tradition behind matcha.